Loading
RPTR-1-201 is an experimental bispecific protein from Repertoire Immune Medicines, in phase 1 trials for advanced solid tumours in people with the HLA-A*02:01 tissue type.
RPTR-1-201 is a tCR bispecific (an engineered T-cell receptor fused to an anti-CD3 domain) from Repertoire Immune Medicines. The engineered T-cell receptor binds a tumour-selective fragment presented by HLA-A*02:01 on cancer cells, and the anti-CD3 part pulls T cells in to kill them. The tumour fragment is not named publicly. Its phase 1/2 study (NCT07293754) is recruiting; the company's pipeline lists colorectal, lung, head and neck, triple-negative breast, pancreatic, gastric, urothelial, cervical and oesophageal cancers. In May 2026 the FDA granted Fast Track designation for HLA-A*02:01-positive unresectable or metastatic triple-negative breast cancer after standard treatment. Whether it works in people has not been established.
The engineered T-cell receptor binds a tumour-selective fragment presented by HLA-A*02:01 on cancer cells, and the anti-CD3 part pulls T cells in to kill them. The tumour fragment is not named publicly. Connects to CD3.
1.One arm of RPTR-1-201 binds CD3 on the cancer cell.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"RPTR-1-201" OR ABSTRACT:"RPTR-1-201") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about RPTR-1-201, not a curated reading list.
Shares CD3 and the tag pipeline.
Shares CD3 and the tag pipeline.
Shares CD3 and the tag pipeline.
Shares CD3 and the tag pipeline.
Shares CD3 and the tag pipeline.
Shares CD3 and the tag pipeline.
Shares CD3 and the tag pipeline.
Shares CD3 and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/